SHAREHOLDER ALERT: FGEN CCXI PCT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / June 3, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
FibroGen, Inc. (NASDAQ:FGEN)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/fibrogen-inc-loss-submission-form?prid=16552&wire=1
Lead Plaintiff Deadline: June 11, 2021
Class Period: October 18, 2017 - April 6, 2021
Allegations against FGEN include that: (i) the Company's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (ii) FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) based on these analyses the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) as a result of the foregoing, Defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
ChemoCentryx, Inc. (NASDAQ:CCXI)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/chemocentryx-inc-loss-submission-form?prid=16552&wire=1
Lead Plaintiff Deadline: July 6, 2021
Class Period: November 26, 2019 - May 3, 2021
Allegations against CCXI include that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx's New Drug Application ("NDA") for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
PureCycle Technologies, Inc. (NASDAQ:PCT)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/purecycle-technologies-inc-loss-submission-form?prid=16552&wire=1
Lead Plaintiff Deadline: July 12, 2021
Class Period: November 16, 2020 - May 5, 2021
Allegations against PCT include that: (i) the technology PureCycle licensed from Procter & Gamble is not proven and presents serious issues even at lab scale; (ii) the challenges posed by the availability and competition for the raw materials necessary to commercialize the licensed technology are significant; (iii) PureCycle's financial projections are baseless; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email firstname.lastname@example.org or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
SOURCE:The Law Offices of Vincent Wong
View source version on accesswire.com:
© 2021 Accesswire. All Rights Reserved.